GSA Capital Partners LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM

GSA Capital Partners LLP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,767 shares of the company’s stock, valued at approximately $579,000.

Several other large investors have also modified their holdings of the stock. Versant Capital Management Inc raised its position in shares of Axsome Therapeutics by 20,300.0% during the third quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after purchasing an additional 203 shares during the period. First Horizon Corp purchased a new position in Axsome Therapeutics in the 3rd quarter worth about $34,000. Essex Investment Management Co. LLC acquired a new stake in Axsome Therapeutics during the 3rd quarter worth about $38,000. UMB Bank n.a. lifted its stake in Axsome Therapeutics by 214.4% during the third quarter. UMB Bank n.a. now owns 371 shares of the company’s stock valued at $45,000 after buying an additional 253 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of Axsome Therapeutics in the third quarter worth about $60,000. 81.49% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on AXSM shares. Weiss Ratings restated a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday, January 21st. Leerink Partners increased their target price on Axsome Therapeutics from $150.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, January 28th. Mizuho set a $230.00 target price on Axsome Therapeutics in a research report on Thursday. Wells Fargo & Company lifted their price target on Axsome Therapeutics from $157.00 to $193.00 and gave the company an “overweight” rating in a report on Tuesday, January 13th. Finally, TD Cowen reissued a “buy” rating on shares of Axsome Therapeutics in a research note on Thursday, January 29th. Sixteen research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Axsome Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $216.07.

Insider Transactions at Axsome Therapeutics

In related news, Director Mark E. Saad sold 37,577 shares of the stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $165.18, for a total value of $6,206,968.86. Following the transaction, the director owned 10,002 shares in the company, valued at approximately $1,652,130.36. This represents a 78.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Ari Maizel sold 7,500 shares of Axsome Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $184.44, for a total transaction of $1,383,300.00. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 308,874 shares of company stock worth $51,390,805. 22.40% of the stock is owned by corporate insiders.

Axsome Therapeutics Trading Down 1.3%

NASDAQ AXSM opened at $183.72 on Monday. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66. Axsome Therapeutics, Inc. has a 1-year low of $86.99 and a 1-year high of $191.50. The firm’s fifty day simple moving average is $173.88 and its 200-day simple moving average is $144.44. The company has a market capitalization of $9.26 billion, a PE ratio of -39.34, a price-to-earnings-growth ratio of 13.22 and a beta of 0.40.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.